LongevityHorizons Zur Startseite
LongevityHorizons
Das Magazin Rubriken Themen Blick ins Magazin Schirmherr Expert:innen Literatur Bibliothek Wissenschaftlicher Beirat Kooperation Kooperation im Detail Herausgeberin Partnernetzwerk Abo & Preise Sonderdrucke & Formulare Mediadaten Abo sichern
Literatur · Ausgabe 01 | 2026

Dr. med. Egor Egorov
Dr. med. Grigori W. Basov

Institut für Präventive und Anti-Aging Medizin, Berlin

Literatur zum gemeinsamen Beitrag von Dr. med. Egor Egorov und Dr. med. Grigori W. Basov.

  1. Navarrete-Opazo A, Mitchell GS. Therapeutic potential of intermittent hypoxia: a matter of dose. Am J Physiol Regul Integr Comp Physiol. 2014;307(10):R1181–R1197. doi:10.1152/ajpregu.00208.2014.
  2. Debevec T, Millet GP, Pialoux V. Hypoxia-induced oxidative stress modulation with physical activity. Front Physiol. 2017;8:84. doi:10.3389/fphys.2017.00084.
  3. Susta D, Glazachev OS, Zapara MA, Dudnik EN, Samartseva VG. Redox homeostasis in humans exposed to intermittent hypoxia-normoxia and to intermittent hypoxia-hyperoxia. High Alt Med Biol. 2020;21(1):45–51. doi:10.1089/ham.2019.0059.
  4. Fratantonio D, Virgili F, Zucchi A, et al. Increasing oxygen partial pressures induce a distinct transcriptional response in human peripheral blood mononuclear cells: a pilot study on the normobaric oxygen paradox. Int J Mol Sci. 2021;22(1):458. doi:10.3390/ijms22010458.
  5. Leveque C, Mrakic-Sposta S, Lafere P, et al. Oxidative stress response’s kinetics after 60 minutes at different (30% or 100%) normobaric hyperoxia exposures. Int J Mol Sci. 2023;24(1):664. doi:10.3390/ijms24010664.
  6. Balestra C, Baldelli S, Virgili F, et al. Pulsed hyperoxia acts on plasmatic advanced glycation end products and advanced oxidation protein products and modulates mitochondrial biogenesis in human peripheral blood mononuclear cells. Int J Mol Sci. 2024;25(4):2394. doi:10.3390/ijms25042394.
  7. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011;21(1):103–115. doi:10.1038/cr.2010.178.
  8. Madden LA, Vince RV, Laden G. The effect of acute hyperoxia in vivo on NF-kappaB expression in human peripheral blood mononuclear cells. Cell Biochem Funct. 2011;29(1):71–73. doi:10.1002/cbf.1712.
  9. Serebrovska TV, Grib ON, Portnichenko VI, Serebrovska ZO, Egorov E, Shatylo VB. Intermittent hypoxia/hyperoxia versus intermittent hypoxia/normoxia: comparative study in prediabetes. High Alt Med Biol. 2019;20(4):383–391. doi:10.1089/ham.2019.0053.
  10. Behrendt T, Bielitzki R, Behrens M, Herold F, Schega L. Effects of intermittent hypoxia-hyperoxia on performance- and health-related outcomes in humans: a systematic review. Sports Med Open. 2022;8(1):70. doi:10.1186/s40798-022-00450-x.
  11. Behrendt T, Bielitzki R, Behrens M, et al. Acute psycho-physiological responses to submaximal constant-load cycling under intermittent hypoxia-hyperoxia versus hypoxia-normoxia in young males. PeerJ. 2024;12:e18027. doi:10.7717/peerj.18027.
  12. Dudnik E, Zagaynaya E, Glazachev OS, Susta D. Intermittent hypoxia-hyperoxia conditioning improves cardiorespiratory fitness in older comorbid cardiac outpatients without hematological changes: a randomized controlled trial. High Alt Med Biol. 2018;19(4):339–343. doi:10.1089/ham.2018.0014.
  13. Bayer U, Likar R, Pinter G, et al. Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients. Alzheimers Dement (N Y). 2017;3(1):114–122. doi:10.1016/j.trci.2017.01.002.
  14. Behrendt T, Altorjay AC, Bielitzki R, Behrens M, Glazachev OS, Schega L. Influence of acute and chronic intermittent hypoxic-hyperoxic exposure prior to aerobic exercise on cardiovascular risk factors in geriatric patients: a randomized controlled trial. Front Physiol. 2022;13:1043536. doi:10.3389/fphys.2022.1043536.
  15. Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry. 2023;28(2):564–578. doi:10.1038/s41380-022-01836-9.
  16. Hofmann H, Önder A, Becker J, et al. Markers of oxidative stress during post-COVID-19 fatigue: a hypothesis-generating, exploratory pilot study on hospital employees. Front Med (Lausanne). 2023;10:1305009. doi:10.3389/fmed.2023.1305009.
  17. Suh HW, Kwon CY, Lee B. Long-term impact of COVID-19 on heart rate variability: a systematic review of observational studies. Healthcare (Basel). 2023;11(8):1095. doi:10.3390/healthcare11081095.
  18. Zha S, Liu X, Yao Y, et al. Short-term intermittent hypoxia exposure for dyspnea and fatigue in post-acute sequelae of COVID-19: a randomized controlled study. Respir Med. 2024;232:107763. doi:10.1016/j.rmed.2024.107763.
  19. Doehner W, Fischer A, Alimi B, et al. Intermittent hypoxic-hyperoxic training during inpatient rehabilitation improves exercise capacity and functional outcome in patients with Long COVID: results of a controlled clinical pilot trial. J Cachexia Sarcopenia Muscle. 2024;15(6):2781–2791. doi:10.1002/jcsm.13628.
  20. World Health Organization. Clinical management of COVID-19: living guideline, June 2025. Geneva: World Health Organization; 2025.
  21. Centers for Disease Control and Prevention. Long COVID Clinical Guidance: Managing post-exertional malaise. Updated March 9, 2026. Accessed July 22, 2026.
  22. Centers for Disease Control and Prevention. Strategies to prevent worsening of symptoms in myalgic encephalomyelitis/chronic fatigue syndrome: post-exertional malaise. Updated May 10, 2024. Accessed July 22, 2026.
  23. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93(5):1043–1065. doi:10.1161/01.CIR.93.5.1043.
  24. Reyes del Paso GA, Langewitz W, Mulder LJM, van Roon A, Duschek S. The utility of low-frequency heart rate variability as an index of sympathetic cardiac tone. Psychophysiology. 2013;50(5):477–487. doi:10.1111/psyp.12027.
  25. Goldstein DS, Bentho O, Park MY, Sharabi Y. Low-frequency power of heart rate variability is not a measure of cardiac sympathetic tone but may be a measure of modulation of cardiac autonomic outflows by baroreflexes. Exp Physiol. 2011;96(12):1255–1261. doi:10.1113/expphysiol.2010.056259.
  26. Billman GE. The LF/HF ratio does not accurately measure cardiac sympatho-vagal balance. Front Physiol. 2013;4:26. doi:10.3389/fphys.2013.00026.
  27. Sévoz-Couche C, Laborde S. Heart rate variability and slow-paced breathing: when coherence meets resonance. Neurosci Biobehav Rev. 2022;135:104576. doi:10.1016/j.neubiorev.2022.104576.
  28. Povea C, Schmitt L, Brugniaux J, Nicolet G, Richalet JP, Fouillot JP. Effects of intermittent hypoxia on heart rate variability during rest and exercise. High Alt Med Biol. 2005;6(3):215–225. doi:10.1089/ham.2005.6.215.
  29. Lizamore CA, Kathiravel Y, Elliott J, Hellemans J, Hamlin MJ. The effect of short-term intermittent hypoxic exposure on heart rate variability in a sedentary population. Physiol Int. 2016;103(1):75–85. doi:10.1556/036.103.2016.1.7.
  30. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics. 2003;13(3):145–157. doi:10.1097/01.fpc.0000054067.64000.8f.
  31. Sutton A, Imbert A, Igoudjil A, et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics. 2005;15(5):311–319. doi:10.1097/01213011-200505000-00006.
  32. Jablonska E, Gromadzinska J, Reszka E, et al. Association between GPx1 Pro198Leu polymorphism, GPx1 activity and plasma selenium concentration in humans. Eur J Nutr. 2009;48(6):383–386. doi:10.1007/s00394-009-0023-0.
  33. Ahn J, Nowell S, McCann SE, et al. Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1217–1222. doi:10.1158/1055-9965.EPI-06-0104.
  34. Manevich Y, Hutchens S, Tew KD, Townsend DM. Allelic variants of glutathione S-transferase P1-1 differentially mediate the peroxidase function of peroxiredoxin VI and alter membrane lipid peroxidation. Free Radic Biol Med. 2013;54:62–70. doi:10.1016/j.freeradbiomed.2012.10.556.
  35. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase: effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75(5):807–821. doi:10.1086/425589.
  36. European Medicines Agency. Guideline on good pharmacogenomic practice. EMA/CHMP/718998/2016. Amsterdam: European Medicines Agency; 2018.
  37. European Parliament and Council of the European Union. Regulation (EU) 2017/746 of 5 April 2017 on in vitro diagnostic medical devices. Off J Eur Union. 2017;L117:176–332.